Milestone Pharmaceuticals enrolls first Canadian patient in ReVeRA-301 Phase 3 AFib-RVR trial for etripamil nasal spray

PUBT · 1d ago
Milestone Pharmaceuticals enrolls first Canadian patient in ReVeRA-301 Phase 3 AFib-RVR trial for etripamil nasal spray
  • Milestone Pharmaceuticals enrolled the first Canadian patient in ReVeRA-301, a Phase 3 pivotal trial of etripamil nasal spray for AFib-RVR.
  • No Phase 3 results have been presented; the study will assess whether at-home dosing can rapidly slow heart rate and ease symptoms.
  • The multinational trial targets about 150 treated AFib-RVR events, using the same repeat-dose regimen marketed in the U.S. as CARDAMYST for PSVT.
  • Strategy centers on a single-study sNDA filing to expand etripamil into AFib-RVR, leveraging safety data generated so far.
  • Phase 2 emergency-room data were previously reported as supportive, showing heart-rate reduction with improved symptom relief and treatment satisfaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9832867) on September 24, 2026, and is solely responsible for the information contained therein.